Where Tech Meets Bio
Subscribe
Sign in
Home
Weekly Highlights
Deep Dives
Sponsored Features
About
Latest
Top
Discussions
Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey
Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic…
Mar 2
•
BiopharmaTrend
and
Roman Kasianov
8
February 2026
Cancer as a Data Problem: What AI Is Doing in Oncology
We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to…
Feb 27
•
BiopharmaTrend
28
5
Weekly Tech+Bio Highlights #74: Big Pharma AI Tie-Ups Lean Toward Real-World Data
Quick run of pharma-AI collaborations, a new startup based on Google's cell sentence tech, and $100 genome sequencing from San Diego
Feb 23
•
BiopharmaTrend
and
Roman Kasianov
16
3
2
Five Genomics Watchpoints for 2026
Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one…
Feb 20
•
BiopharmaTrend
25
3
Weekly Tech+Bio Highlights #72-73: Mid-Month Rundown
Mid-February highlights across AI drug discovery, gene therapy lane, IPO and M&A watch, and a few broader ecosystem notes
Feb 16
•
BiopharmaTrend
and
Roman Kasianov
10
3
New-Modality Drugs Behind Today’s Big Headlines
How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets
Feb 12
•
BiopharmaTrend
19
3
Five Women Shaping the AI-Life Science Stack: International Day of Women and Girls in Science Special
On this UN observance, we profile five women building the AI-driven life sciences stack from discovery to clinic, while examining persistent gender gaps…
Feb 11
•
BiopharmaTrend
16
2
Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China
Feb 9
•
BiopharmaTrend
20
3
How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy
Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff…
Feb 6
•
BiopharmaTrend
18
3
Weekly Tech+Bio Highlights #71: More China Deals
DeepMind's new deep learning model lands in Nature, Big Pharma's $18B+ plans for China, FDA clears first epigenetic reprogramming trial
Feb 2
•
Roman Kasianov
and
BiopharmaTrend
9
1
January 2026
Weekly Tech+Bio Highlights #70: Signals from a Quieter Week
Isomorphic Labs x J&J platform deal, LLM “gym” for pharma R&D, Absci’s new antibody model, and more
Jan 26
•
Roman Kasianov
and
BiopharmaTrend
8
2
2
Weekly Tech+Bio Highlights #69: Big Pharma Keeps Tapping Multimodal AI Stacks
JPM takeaways; reality check on de novo antibody design; 2026 biotech & clinical AI reports, and more
Jan 19
•
Roman Kasianov
and
BiopharmaTrend
14
2
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
